Cullinan Therapeutics (CGEM) Interest & Investment Income (2020 - 2026)

Cullinan Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 37.72% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $19.7 million (down 35.41% YoY), while the FY2025 annual figure was $22.2 million, down 25.11% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $4.1 million, down from $4.6 million in the prior quarter.
• The five-year high for Interest & Investment Income was $8.4 million in Q3 2024, with the low at $197000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $5.3 million (2023), against an average of $5.0 million.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 2355.47% in 2022, then plunged 39.25% in 2025.
• Cullinan Therapeutics' Interest & Investment Income stood at $3.4 million in 2022, then surged by 75.89% to $5.9 million in 2023, then increased by 26.96% to $7.5 million in 2024, then slumped by 38.56% to $4.6 million in 2025, then fell by 11.2% to $4.1 million in 2026.
• Business Quant data shows CGEM's Interest & Investment Income at $4.1 million in Q1 2026, $4.6 million in Q4 2025, and $5.1 million in Q3 2025.